Group 1 - The core viewpoint of the article highlights the successful progress of Huazhan Biotechnology's listing process, with its unique PDGF drug pipeline and broad market prospects attracting significant industry attention [1] - Huazhan Biotechnology, established in 2012, has developed ten candidate products covering 14 types of wound healing indications, with a competitive advantage in its core product matrix [1] - Pro-101-1 is noted as the fastest PDGF candidate drug for treating burns in clinical development in China, while Pro-101-2 targets diabetic foot ulcers, addressing a significant market gap and providing hope for patients [1] Group 2 - The increasing prevalence of diabetes, driven by an aging population and unhealthy lifestyles, is leading to a rise in diabetic foot ulcer cases, with a concerning trend of younger patients being affected [1] - According to a Frost & Sullivan report, a diabetic patient faces amputation risk every 20 seconds globally, with a mortality rate of 22% among amputees, indicating a pressing clinical treatment demand [1] - Huazhan Biotechnology's PDGF core products target hard-to-heal wounds, with a substantial market size in the wound healing sector and potential access to a trillion-level consumer healthcare market, showcasing significant commercialization potential and social impact [1]

Core Viewpoint - The research paper on the clinical efficacy and safety of "Tangening Tongluo Tablets combined with Tangening Tongluo Ointment for Type 2 Diabetic Foot Ulcers" has been published, indicating significant healing effects and clinical value for diabetic foot patients [1] Group 1 - The study was led by Professor Gu Yunjuan from Nantong University Affiliated Hospital and was sponsored by Guizhou Bailing [1] - Results show that both Tangening Tongluo Tablets and Ointment significantly promote the healing of diabetic foot ulcers [1] - The combined treatment demonstrates superior long-term effects, enhancing local immunity, inhibiting bacterial growth, and reducing infection risks [1] Group 2 - The research improves the clinical prognosis for diabetic foot patients, highlighting its high clinical application value [1]